Benign skull and subdural lesions in patients with prior medulloblastoma therapy

Kristiyana Kaneva*, Nitin Wadhwani, Arthur J. DiPatri, Susan Palasis, Stewart Goldman, Jessie Aw-Zoretic

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Purpose: To report on our institutional cohort of patients and review the literature of medulloblastoma patients who developed skull/subdural-based lesions following treatment. Methods: Following institutional review board (IRB) approval, we retrospectively reviewed the medical records of four children with a history of treated medulloblastoma who developed non-specific skull-based/subdural lesions incidentally found on surveillance imaging. Results: Biopsies of the lesions proved the pathology to be low grade and included inflammatory myofibroblastic tumor, cortical fibrous defect consistent with fibroma, fibrous tissue, and fibrous dysplasia. The finding of calvarial or subdural fibrous lesions in children following therapy for medulloblastoma was noted in four out of 201 (136 with available follow-up data) medulloblastoma patients seen or discussed in our institution over the past 10 years. Conclusions: These lesions can grow over time and pose a differential diagnostic challenge with metastatic disease when identified. The skull and subdural space should be scrutinized for secondary lesions on surveillance imaging of patients with medulloblastoma who have received craniospinal irradiation as knowledge of this benign occurrence will assist with management.

Original languageEnglish (US)
Pages (from-to)359-366
Number of pages8
JournalChild's Nervous System
Volume37
Issue number2
DOIs
StatePublished - Feb 2021

Keywords

  • Bone lesions
  • Fibrous
  • Medulloblastoma
  • Pediatric brain tumor
  • Skull lesion

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Benign skull and subdural lesions in patients with prior medulloblastoma therapy'. Together they form a unique fingerprint.

Cite this